Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 ...
ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ...
The SURPASS study is enrolling patients at research sites across the U.S. and EuropeELA026 targets signal regulatory proteins (SIRP) as a novel ...
A research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU Department of Applied Biology and Chemical ...
BUFFALO, N.Y. — When you pop a prescription pill into your mouth, you trust it to address the issue it was meant to fix. But what really happens? How is your body processing the drugs and what happens ...